Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial.

Date publication

mars 2026

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Bennett JL, Bhattacharyya S, Zabeti A, Levy M, de Sèze J, Taney MJ, Parks B, Allen K, Akpoji U, Pittock SJ

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41782198

Résumé

This post hoc analysis of the CHAMPION-NMOSD trial evaluated the safety and efficacy of ravulizumab in patients with aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) previously exposed or naïve to rituximab (RTX).

Mots clés

Aquaporin-4 antibody-positive, meningococcal vaccination, neuromyelitis optica spectrum disorder, ravulizumab, rituximab, safety profile

Référence

Mult Scler. 2026 03 4;:13524585261425076